EUCTR2017-004262-95-IT进行中（未招募）1 期
Phase III, Multinational, Multicenter, Investigator-Masked, Randomised, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocular Hypertension over a 3-Month period, followed by a 12-Month Follow-Up with Open-Label DE-130A Treatment - International clinical study comparing the efficacy and safety of DE-130A with Xalatan® in patients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- SANTEN SAS
- 入组人数
- 380
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male or female, 18 years of age or older
- •-Diagnosis of OAG (primary open angle glaucoma, pseudo exfoliative glaucoma, or pigmentary glaucoma), or OHT in eligible eye(s) currently on monotherapy.
- •-Unilateral OAG, or OHT are permissible as long as the physician does not anticipate significant IOP changes to the fellow eye that would require treatment during the duration of the study.
- •-Current treatment with monotherapy for OAG or OHT with a controlled IOP = 18 mmHg in each eye (pre-washout).
- •-Stable visual field.
- •-Post-washout IOP = 22 mmHg in at least one eye
- •-Post-washout IOP = 32 mmHg in both eyes
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 75
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 305
排除标准
- •-Any form of glaucoma other than primary open angle glaucoma, pseudo exfoliative glaucoma, and pigmentary glaucoma in either eye.
- •-IOP at any time point during the Screening or Baseline visits (Visits 1 or 2) of > 32 mmHg in either eye.
- •-Current treatment for glaucoma with a fixed-combination therapy or more than one drug or with an oral drug within 6 months prior to screening.
- •-Corneal abnormalities that would interfere with accurate IOP readings with an applanation tonometer in either eye.
- •-Central corneal thickness = 480 µm or = 600 µm in either eye (historical value or at the screening visit)
- •-Significant visual field loss (absolute defect in the 10° central point or mean deviation worse than -12 dB) or progressive field loss during the year before screening.
- •-Significant optic nerve abnormality, other than glaucomatous abnormalities in the opinion of the investigator as determined by ophthalmoscopy.
- •-Significant changes of the optic neuropathy (e.g. increase cupping since the last examination, optic nerve hemorrhage)
- •-Inability to visualize the patient's optic nerve.
- •-Gonioscopy consistent with potential angle closure glaucoma.
- •-Patients with severe blepharitis and/or Meibomian Gland Disease (MGD). Patients enrolled with mild to moderate blepharitis and/or MGD should be treated as appropriate during the study
- •-Any active ocular disease
- •-Intraocular surgery within 6 months prior to screening.
- •-Past history of any filtering surgery for glaucoma.
- •-Refractive surgery of any type within 1 year prior to screening
- •-Anticipated alteration in chronic therapy with or introduction of agents known to have a substantial effect on IOP
研究者
相似试验
进行中（未招募）
1 期
International clinical study comparing the efficacy and safety of DE-130A with Xalatan® in patients with glaucoma (high pressure inside the eye).EUCTR2017-004262-95-GBSanten SAS380
进行中（未招募）
1 期
International clinical study comparing the efficacy and safety of DE-130A with Xalatan® in patients with glaucoma (high pressure inside the eye).Open-Angle Glaucoma or Ocular HypertensionMedDRA version: 20.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: PTClassification code 10030043Term: Ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2017-004262-95-EESanten SAS380
进行中（未招募）
1 期
International clinical study comparing the efficacy and safety of DE-130A with Xalatan® in patients with glaucoma (high pressure inside the eye).EUCTR2017-004262-95-FISanten SAS380
进行中（未招募）
1 期
International clinical study comparing the efficacy and safety of DE-130A with Xalatan® in patients with glaucoma (high pressure inside the eye).Open-Angle Glaucoma or Ocular HypertensionMedDRA version: 20.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: PTClassification code 10030043Term: Ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2017-004262-95-PLSanten SAS380
进行中（未招募）
1 期
International clinical study comparing the efficacy and safety of DE-130A with Xalatan® in patients with glaucoma (high pressure inside the eye).Open-Angle Glaucoma or Ocular HypertensionMedDRA version: 20.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: PTClassification code 10030043Term: Ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2017-004262-95-ESSanten SAS380